These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33492017)

  • 1. Plasmatic Coagulation Capacity Correlates With Inflammation and Abacavir Use During Chronic HIV Infection.
    van der Heijden WA; Wan J; Van de Wijer L; Jaeger M; Netea MG; van der Ven AJ; de Groot PG; Roest M; de Mast Q
    J Acquir Immune Defic Syndr; 2021 May; 87(1):711-719. PubMed ID: 33492017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in D-dimer after initiation of antiretroviral therapy in adults living with HIV in Kenya.
    Teasdale CA; Hernandez C; Zerbe A; Chege D; Hawken M; El-Sadr WM
    BMC Infect Dis; 2020 Jul; 20(1):508. PubMed ID: 32664854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.
    Palella FJ; Gange SJ; Benning L; Jacobson L; Kaplan RC; Landay AL; Tracy RP; Elion R
    AIDS; 2010 Jul; 24(11):1657-65. PubMed ID: 20588104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer.
    Taylor BS; So-Armah K; Tate JP; Marconi VC; Koethe JR; Bedimo RJ; Butt AA; Gibert CL; Goetz MB; Rodriguez-Barradas MC; Womack JA; Gerschenson M; Lo Re V; Rimland D; Yin MT; Leaf D; Tracy RP; Justice AC; Freiberg MS
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):500-508. PubMed ID: 28696344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People?
    So-Armah KA; Tate JP; Chang CH; Butt AA; Gerschenson M; Gibert CL; Leaf D; Rimland D; Rodriguez-Barradas MC; Budoff MJ; Samet JH; Kuller LH; Deeks SG; Crothers K; Tracy RP; Crane HM; Sajadi MM; Tindle HA; Justice AC; Freiberg MS;
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):206-213. PubMed ID: 27824677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
    Kuller LH; Tracy R; Belloso W; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren J; Neuhaus J; Nixon D; Paton NI; Neaton JD;
    PLoS Med; 2008 Oct; 5(10):e203. PubMed ID: 18942885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is low-level HIV-1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?
    Elvstam O; Medstrand P; Jansson M; Isberg PE; Gisslén M; Björkman P
    HIV Med; 2019 Oct; 20(9):571-580. PubMed ID: 31148335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.
    Baker JV; Neuhaus J; Duprez D; Kuller LH; Tracy R; Belloso WH; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren J; Nixon DE; Paton NI; Neaton JD;
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):36-43. PubMed ID: 20930640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217.
    Macatangay BJ; Yang M; Sun X; Morton J; De Gruttola V; Little S; Hogan C; Rinaldo CR;
    J Acquir Immune Defic Syndr; 2017 May; 75(1):137-141. PubMed ID: 28198712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of T-Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV.
    Sinha A; Ma Y; Scherzer R; Hur S; Li D; Ganz P; Deeks SG; Hsue PY
    J Am Heart Assoc; 2016 Dec; 5(12):. PubMed ID: 27998918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals.
    Jong E; Louw S; van Gorp EC; Meijers JC; ten Cate H; Jacobson BF
    Thromb Haemost; 2010 Dec; 104(6):1228-34. PubMed ID: 20886182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir use is associated with increased prothrombin conversion.
    Yan Q; Huang S; van der Heijden W; Ninivaggi M; van de Wijer L; de Laat-Kremers R; Van der Ven AJ; de Laat B; de Mast Q
    Front Immunol; 2023; 14():1182942. PubMed ID: 37122705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy.
    Jong E; Louw S; Meijers JC; de Kruif MD; ten Cate H; Büller HR; Mulder JW; van Gorp EC
    AIDS Patient Care STDS; 2009 Dec; 23(12):1001-7. PubMed ID: 19929230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of inhalable particulate matter on blood coagulation.
    Bonzini M; Tripodi A; Artoni A; Tarantini L; Marinelli B; Bertazzi PA; Apostoli P; Baccarelli A
    J Thromb Haemost; 2010 Apr; 8(4):662-8. PubMed ID: 19922434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
    Patel P; Bush T; Overton T; Baker J; Hammer J; Kojic E; Conley L; Henry K; Brooks JT;
    Antivir Ther; 2012; 17(4):755-61. PubMed ID: 22301072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.
    Sereti I; Krebs SJ; Phanuphak N; Fletcher JL; Slike B; Pinyakorn S; O'Connell RJ; Rupert A; Chomont N; Valcour V; Kim JH; Robb ML; Michael NL; Douek DC; Ananworanich J; Utay NS;
    Clin Infect Dis; 2017 Jan; 64(2):124-131. PubMed ID: 27737952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation.
    Armah KA; McGinnis K; Baker J; Gibert C; Butt AA; Bryant KJ; Goetz M; Tracy R; Oursler KK; Rimland D; Crothers K; Rodriguez-Barradas M; Crystal S; Gordon A; Kraemer K; Brown S; Gerschenson M; Leaf DA; Deeks SG; Rinaldo C; Kuller LH; Justice A; Freiberg M
    Clin Infect Dis; 2012 Jul; 55(1):126-36. PubMed ID: 22534147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Inflammation and the Increased Risk of Inflamm-Aging and Age-Associated Diseases in People Living With HIV on Long Term Suppressive Antiretroviral Therapy.
    Babu H; Ambikan AT; Gabriel EE; Svensson Akusjärvi S; Palaniappan AN; Sundaraj V; Mupanni NR; Sperk M; Cheedarla N; Sridhar R; Tripathy SP; Nowak P; Hanna LE; Neogi U
    Front Immunol; 2019; 10():1965. PubMed ID: 31507593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.
    Silva EF; Charreau I; Gourmel B; Mourah S; Kalidi I; Guillon B; De Castro N; Caron F; Braun J; Molina JM;
    J Infect Dis; 2013 Sep; 208(6):892-7. PubMed ID: 23801606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.